The purpose of the research is to develop a statistical decision support algorithm for patients who may benefit from Adjuvant Cisplatin/Vinorelbine (ACT) and improve their survival rates. Genome-wide microarray data will be used to identify feasible sets of genes and probe sets that constitute the gene signature. The data are available at the National Center for Biotechnology Information Gene Expression Omnibus (GSE14814). Preliminary studies have shown that high risk patients that received ACT resulted in an improved prognosis. However, low risk patients showed no benefit from ACT and the treatment was possibly detrimental to the patient. Studies using random forests models have shown that genomic markers could potentially identify a patient’s risk factor and likelihood to benefit from ACT; however, it was noted that the random forests do not provide an estimate of the strength of the treatment effect, nor is it possible to clearly identify subgroups of patients with similar responses to ACT treatment. Building on this idea, Accelerated Failure Time models are used to predict the probability of benefit from receiving chemotherapy or surgery only and provide a treatment recommendation. We showed that regardless of whether the model recommended chemotherapy or surgery only, patients that followed the treatment recommendation had significantly longer survival times than patients that did not. For new patients, the model can provide the likelihood of benefit for each treatment based on a small number of genomic biomarkers.
|Commitee:||Kim, Sung Eun, Zhou, Tianni|
|School:||California State University, Long Beach|
|Department:||Mathematics and Statistics|
|School Location:||United States -- California|
|Source:||MAI 56/04M(E), Masters Abstracts International|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be